| 10.13 -1.08 (-9.63%) | 05-23 09:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.75 | 1-year : | 16.07 |
| Resists | First : | 11.77 | Second : | 13.75 |
| Pivot price | 10.24 |
|||
| Supports | First : | 9.39 |
Second : | 7.92 |
| MAs | MA(5) : | 11.08 |
MA(20) : | 10.03 |
| MA(100) : | 10.29  |
MA(250) : | 11.62 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 79.2 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 19 | Low : | 6.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GYRE ] has closed below upper band by 26.1%. Bollinger Bands are 24.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.32 - 11.38 | 11.38 - 11.42 |
| Low: | 10.09 - 10.15 | 10.15 - 10.2 |
| Close: | 11.12 - 11.21 | 11.21 - 11.3 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Fri, 23 May 2025
Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com
Fri, 23 May 2025
Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus
Thu, 22 May 2025
Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan
Thu, 22 May 2025
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance
Thu, 22 May 2025
Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial - TipRanks
Thu, 22 May 2025
Gyre Therapeutics launches public stock offering By Investing.com - Investing.com India
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 85 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 2,370 (K) |
| Shares Short P.Month | 2,390 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | 7.1 % |
| Operating Margin | 10.3 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 12.1 % |
| Qtrly Rev. Growth | -18.8 % |
| Gross Profit (p.s.) | 1.03 |
| Sales Per Share | 1.07 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | -70.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 224.19 |
| PEG Ratio | 0 |
| Price to Book value | 14.37 |
| Price to Sales | 10.44 |
| Price to Cash Flow | 0 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 32.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|